Societal CDMO (SCTL) 10-Q 11 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 10, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	REPH
Entity Registrant Name	Recro Pharma, Inc.
Entity Central Index Key	1,588,972
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		19,050,966

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 19,485	$ 64,483
Short-term investments	36,060
Accounts receivable	12,278	10,411
Inventory	7,810	8,746
Prepaid expenses and other current assets	1,636	1,118
Total current assets	77,269	84,758
Property, plant and equipment, net	37,277	37,300
Deferred income taxes	18,295	17,060
Intangible assets, net	36,787	37,433
Goodwill	6,446	6,446
Total assets	176,074	182,997
Current liabilities:
Accounts payable	2,954	4,132
Accrued expenses	8,137	9,893
Current portion of long-term debt, net	1,851	2,236
Total current liabilities	12,942	16,261
Long-term debt, net	22,695	22,152
Warrants	3,688	3,397
Contingent consideration	72,388	69,574
Total liabilities	111,713	111,384
Commitments and contingencies (Note 11)
Shareholders’ equity:
Preferred stock, $0.01 par value. Authorized, 10,000,000 shares; none issued and outstanding
Common stock, $0.01 par value. Authorized, 50,000,000 shares; issued and outstanding, 19,050,966 shares at March 31, 2017 and 19,043,216 shares at December 31, 2016	190	190
Additional paid-in capital	133,583	132,691
Accumulated deficit	(69,355)	(61,268)
Accumulated other comprehensive loss	(57)
Total shareholders’ equity	64,361	71,613
Total liabilities and shareholders’ equity	$ 176,074	$ 182,997

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	19,050,966	19,043,216
Common stock, shares outstanding	19,050,966	19,043,216

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Manufacturing, royalty and profit sharing revenue	$ 18,128	$ 17,138
Research and development revenue	614	604
Total revenues	18,742	17,742
Operating expenses:
Cost of sales (excluding amortization of intangible assets)	10,498	10,271
Research and development	7,763	7,808
General and administrative	4,032	2,658
Amortization of intangible assets	646	646
Change in warrant valuation	291	(1,594)
Change in contingent consideration valuation	2,814	2,978
Total operating expenses	26,044	22,767
Operating loss	(7,302)	(5,025)
Other income (expense):
Interest income	105	9
Interest expense	(1,183)	(1,512)
Net loss before income taxes	(8,380)	(6,528)
Income tax benefit (expense)	293	(11)
Net loss	$ (8,087)	$ (6,539)
Basic and diluted net loss per common share	$ (0.42)	$ (0.71)
Weighted average basic and diluted common shares outstanding	19,049,416	9,251,948
Other comprehensive loss:
Unrealized loss on available-for-sale securities	$ (57)
Comprehensive loss	$ (8,144)	$ (6,539)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - 3 months ended Mar. 31, 2017 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2016	$ 71,613	$ 190	$ 132,691	$ (61,268)
Balance, Shares at Dec. 31, 2016		19,043,216
Stock-based compensation expense	892		892
Issuance of restricted stock units, Shares		7,750
Other comprehensive loss	(57)				$ (57)
Net loss	(8,087)			(8,087)
Balance at Mar. 31, 2017	$ 64,361	$ 190	$ 133,583	$ (69,355)	$ (57)
Balance, Shares at Mar. 31, 2017		19,050,966

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (8,087)	$ (6,539)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	892	701
Non-cash interest expense	158	296
Depreciation expense	1,196	1,271
Amortization of intangible assets	646	646
Change in warrant valuation	291	(1,594)
Change in contingent consideration valuation	2,814	2,978
Deferred income taxes	(1,235)	(406)
Changes in operating assets and liabilities, net of effect of acquisition:
Inventory	936	1,344
Prepaid expenses and other current assets	(518)	(177)
Accounts receivable	(1,867)	(3,589)
Accounts payable and accrued expenses	(2,363)	2,624
Net cash used in operating activities	(7,137)	(2,445)
Cash flows from investing activities:
Purchase of property and equipment	(1,744)	(344)
Purchase of short-term investments	(36,117)
Net cash used in investing activities	(37,861)	(344)
Cash flows from financing activities:
Proceeds from Aspire facility		560
Payments on long-term debt		(2,633)
Net cash used in financing activities		(2,073)
Net decrease in cash and cash equivalents	(44,998)	(4,862)
Cash and cash equivalents, beginning of year	64,483	19,779
Cash and cash equivalents, end of year	19,485	14,917
Supplemental disclosure of cash flow information:
Cash paid for interest	1,026	$ 1,215
Unrealized loss on available-for-sale securities	57
Purchase of property, plant and equipment included in accrued expenses and accounts payable	$ 237

Background

Background	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Background	(1) Background Recro Pharma, Inc., or the Company, was incorporated in Pennsylvania on November 15, 2007. The Company is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating contract development and manufacturing, or CDMO division. Each of these divisions are deemed to be reportable segments (see Note 3(n) and Note 14). The Acute Care division is primarily focused on developing innovative products for hospital and related settings, and the CDMO division leverages the Company’s formulation expertise to develop and manufacture pharmaceutical products using the Company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. On April 10, 2015, the Company acquired from Alkermes plc, or Alkermes, worldwide rights to intravenous and intramuscular, or injectable meloxicam, a proprietary, Phase III-ready, long-acting preferential COX-2 inhibitor for the management of moderate to severe pain, as well as a contract manufacturing facility, royalty and formulation business in Gainesville, Georgia. The acquisition is referred to herein as the Gainesville Transaction.

Development-Stage Risks and Liq

Development-Stage Risks and Liquidity	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Development-Stage Risks and Liquidity	(2) Development-Stage Risks and Liquidity The Company has incurred losses from operations since inception and has an accumulated deficit of $69,355 as of March 31, 2017. Though its CDMO segment has been profitable, the Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its products currently in development. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates, including the payment of the Gainesville Transaction contingent payments, which may become due upon achievement of certain development and commercialization milestones for meloxicam. The Company’s future operations are highly dependent on a combination of factors, including (i) the continued profitability of the CDMO segment; (ii) the timely and successful completion of additional financing and/or alternative sources of capital, debt or partnering transactions; (iii) the success of its research and development, including the results and timing of its clinical trials; (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies; and, ultimately, (v) regulatory approval and market acceptance of the Company’s proposed future products. Management believes that the Company’s existing cash as of March 31, 2017 will be sufficient to fund its operations through mid-year 2018.

Summary of Significant Accounti

Summary of Significant Accounting Principles	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Principles	(3) Summary of Significant Accounting Principles (a) Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of March 31, 2017 and its results of operations and cash flows for the three months ended March 31, 2017 and 2016. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The consolidated interim financial statements, presented herein, do not contain the required disclosures under U.S. GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. (b) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. (c) Cash, Cash Equivalents and Short-term Investments The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents as of March 31, 2017 and 2016 consisted of money market mutual funds and U.S. Government and agency bonds. Short-term investments consisted of U.S. Government and agency bonds with maturities of less than one year. The Company classifies all of its short-term investments as “available-for-sale.” In general, these investments are free of trading restrictions. The Company carries these investments at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses are included in accumulated other comprehensive loss, which is reflected as a separate component of shareholders’ equity in the Company’s consolidated balance sheets. Gains and losses are recognized when realized in the Company’s consolidated statements of income. When the Company has determined that an other-than-temporary decline in fair value has occurred, the amount of the decline that is related to a credit loss is recognized in income. Gains and losses are determined using the specific identification method. (d) Fair Value of Financial Instruments Management believes that the carrying amounts of the Company’s financial instruments, including cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, approximate fair value due to the short-term nature of those instruments. Management believes the carrying value of debt approximates fair value as the interest rates are reflective of the rate the Company could obtain on debt with similar terms and conditions. (e) Inventory Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Included in inventory are raw materials used in production of commercial products. (f) Property and Equipment Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture and office equipment; six to ten or more years for manufacturing equipment; two to five years for vehicles; 35 to 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance cost are expensed as incurred. (g) Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized, but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment model prescribes a two-step method for determining impairment. The first step compares a reporting unit’s fair value to its carrying amount to identify potential goodwill impairment. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the second step of the impairment test must be completed to measure the amount of the reporting unit’s goodwill impairment loss, if any. Step two requires an assignment of the reporting unit’s fair value to the reporting unit’s assets and liabilities to determine the implied fair value of the reporting unit’s goodwill. The implied fair value of the reporting unit’s goodwill is then compared with the carrying amount of the reporting unit’s goodwill to determine the goodwill impairment loss to be recognized, if any. Intangible assets include the Company’s royalties and contract manufacturing relationships intangible asset as well as an in-process research and development, or IPR&D, asset. The royalties and contract manufacturing relationships intangible asset is considered a definite-lived intangible asset and is amortized on a straight-line basis over a useful life of six years. Intangible assets related to IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off, and the Company will record a noncash impairment loss on its consolidated statements of operations. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. The impairment test for indefinite-lived intangible assets is a one-step test, which compares the fair value of the intangible asset to its carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to the excess. Based on accounting standards, it is required that these assets be assessed at least annually for impairment unless a triggering event occurs between annual assessments, which would then require an assessment in the period which a triggering event occurred. (h) Revenue Recognition The Company generates revenues from manufacturing, packaging and related services for multiple pharmaceutical companies. The agreements that the Company has with its commercial partners provide for manufacturing revenues, royalties and/or profit sharing components. Manufacturing and other related services revenue is recognized when persuasive evidence of an arrangement exists, shipment has occurred and the title to the product and associated risk of loss has passed to the customer, the sales price is fixed or determinable and collectability is reasonably assured. In addition to manufacturing and packaging revenue, the customer agreements have royalties and/or profit sharing payments, computed on the net product sales of the partner. Royalty and profit sharing revenues are generally recognized under the terms of the license and supply agreement in the period the products are sold and expenses are incurred by the Company’s CDMO commercial partner and when collectability is reasonably assured. Revenues related to research and development are generally recognized as the related services or activities are performed, in accordance with the contract terms. To the extent that the agreements specify services are to be performed on a fixed basis, revenues are recognized consistent with the pattern of the work performed. In agreements which specify milestones, the related revenues are recognized upon the achievement of a substantive milestone. (i) Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company’s policy is to limit the amount of credit exposure to any one financial institution and place its cash and cash equivalents with financial institutions evaluated as being creditworthy. To date, the Company has not experienced any losses on its cash equivalents. (j) Research and Development Research and development costs for the Company’s proprietary products/product candidates are charged to expense as incurred. Research and development expenses consist primarily of funds paid to third parties for the provision of services for manufacturing of clinical supplies, drug development, clinical trials, statistical analysis and report writing and regulatory compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expenses relating to these costs. Upfront and milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired IPR&D if the technology licensed has not reached technological feasibility and has no alternative future use. (k) Stock-Based Awards The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of options grants. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Non-employee stock-based awards are revalued until an award vests and the Company recognizes compensation expense on a straight-line basis over the vesting period of each separated vesting tranche of the award, which is known as the accelerated attribution method. The estimation of the number of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company’s current estimates, such amounts are recognized as an adjustment in the period in which estimates are revised. (l) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company accrues interest, and related penalties are classified as income tax expense in the Consolidated Statements of Operations. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year. (m) Net Loss Per Common Share Basic net loss per common share is determined by dividing net loss by the weighted average common shares outstanding during the period. For all periods presented, the outstanding common stock options, unvested restricted stock units and warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of March 31, 2017 and 2016, as they would be anti-dilutive: March 31, 2017 2016 Options and restricted stock units outstanding 3,337,461 2,224,123 Warrants 784,928 784,928 Amounts in the table above reflect the common stock equivalents of the noted instruments. (n) Segment Information The Company determined its reportable segments based on its strategic business units, the commonalities among the products and services within each segment and the manner in which the Company reviews and evaluates operating performance. The Company has identified CDMO and Acute Care as reportable segments. Segment disclosures are included in Note 14. Segment operating profit (loss) is defined as segment revenue less segment operating expenses (segment operating expenses consist of general and administrative expenses, research and development expenses, and the change in valuation of contingent consideration and warrants). The following items are excluded from segment operating profit (loss): interest income and expense, and income tax benefit (expense). Segment assets are those assets and liabilities that are recorded and reported by segment operations. Segment operating capital employed represents segment assets less segment liabilities. (o) Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board, or FASB, issued updated guidance on the annual goodwill impairment test. The amended guidance allows companies to apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit’s carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The amendments of the Accounting Standards Update, or ASU, are effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the effect that this guidance may have on its consolidated financial statements. In August 2016, the FASB issued updated guidance in the classification of certain cash receipts and payments in the statement of cash flows where diversity in practice exists. This new guidance is effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In March 2016, the FASB issued updated guidance on the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, employee tax withholding, calculation of shares for use in diluted earnings per share and the classification on the statement of cash flows. The new guidance is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company early adopted the guidance effective July 1, 2016. The guidance did not have a material impact to the consolidated financial statements upon adoption. In February 2016, the FASB issued updated guidance regarding the accounting for and disclosures of leases. This new ASU represents a wholesale change to lease accounting and introduces a lease model that brings most leases on the balance sheet. It also eliminates the required use of bright-line tests in current U.S. GAAP for determining lease classification. The new guidance is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect that this guidance may have on its consolidated financial statements. In September 2015, the FASB issued updated guidance regarding the accounting for and disclosure of measurement-period adjustments that occur in periods after a business combination is consummated. This update requires that the acquirer recognize measurement-period adjustments in the reporting period in which they are determined. Prior period information should not be revised. This update also requires an entity to present separately on the face of the income statement or disclose in the notes the amount recorded in the current-period income statement that would have been recorded in previous reporting periods if the adjustments had been recognized as of the acquisition date. The updated guidance is effective for annual and interim periods beginning after December 15, 2016. The Company adopted the guidance effective January 1, 2017. The guidance did not have a material impact to the consolidated financial satements upon adoption. In July 2015, the FASB issued updated guidance which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. The amendments in this guidance do not apply to inventory that is measured using last-in, first-out, or LIFO, or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. Within the scope of this new guidance, an entity should measure inventory at the lower of cost and net realizable value; where net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The new guidance is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The new guidance must be applied on a prospective basis. The Company adopted the guidance effective January 1, 2017. The guidance did not have a material impact to the consolidated financial satements upon adoption. In May 2014, the FASB issued updated guidance regarding the accounting for and disclosures of revenue recognition, with an effective date for annual and interim periods beginning after December 15, 2016. The update provides a single comprehensive model for accounting for revenue from contracts with customers. The model requires that revenue recognized reflect the actual consideration to which the entity expects to be entitled in exchange for the goods or services defined in the contract, including in situations with multiple performance obligations. In July 2015, the FASB deferred the effective date by one year. The guidance will be effective for annual and interim periods beginning after December 15, 2017. The new standard permits two methods of adoption: the full retrospective method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company currently anticipates adopting the standard using the modified retrospective method. The Company plans to complete an analysis of existing contracts with its customers and to assess the differences in accounting for such contracts under ASU 2014-09 compared with current revenue accounting standards by the end of the third quarter. The new standard will result in additional revenue-related disclosures in the footnotes to the consolidated financial statements. The Company will continue to assess new customer contracts during 2017. Adoption of this standard will require changes to business processes, systems and controls to support the additional required disclosures. The Company is in the process of identifying such changes.

Acquisition of Gainesville Faci

Acquisition of Gainesville Facility and Meloxicam	3 Months Ended
	Mar. 31, 2017
Gainesville [Member]
Acquisition of Gainesville Facility and Meloxicam	(4) Acquisition of Gainesville Facility and Meloxicam On April 10, 2015, the Company completed the Gainesville Transaction. The consideration paid in connection with the Acquisition consisted of $50.0 million cash at closing, a $4.0 million working capital adjustment and a seven-year warrant to purchase 350,000 shares of the Company’s common stock at an exercise price of $19.46 per share. In addition, the Company may be required to pay up to an additional $125.0 million in milestone payments (including, at the Company’s election, either (i) $10 million upon a new drug application, or NDA, filing and $30 million upon regulatory approval or (ii) an aggregate of $45 million upon regulatory approval, as well as net sales milestones related to injectable meloxicam) and a percentage of future product net sales related to injectable meloxicam between 10% and 12% (subject to a 30% reduction when no longer covered by patent). Under the acquisition method of accounting, the consideration paid and the fair value of the contingent consideration and royalties are allocated to the fair value of the assets acquired and liabilities assumed. The contingent consideration obligation is remeasured each reporting date with changes in fair value recognized as a period charge within the statement of operations (see note 5 for further information regarding fair value). The contingent consideration consists of three separate components. The first component consists of two potential payments, which will be payable upon the submission of the NDA for meloxicam and the related regulatory approval or one payment upon regulatory approval. The second component consists of three potential payments, based on the achievement of specified annual revenue targets. The third component consists of a royalty payment for a defined term on future meloxicam net sales. The fair value of the first contingent consideration component recognized on the acquisition date was estimated by applying a risk-adjusted discount rate to the probability-adjusted contingent payments and the expected approval dates. The fair value of the second contingent consideration component recognized on the acquisition date was estimated by applying a risk-adjusted discount rate to the potential payments resulting from probability-weighted revenue projections and expected revenue target attainment dates. The fair value of the third contingent consideration component recognized on the acquisition date was estimated by applying a risk-adjusted discount rate to the potential payments resulting from probability-weighted revenue projections and the defined royalty percentage. These fair values are based on significant inputs not observable in the market, which are referred to in the guidance as Level 3 inputs. The contingent consideration components are classified as liabilities and are subject to the recognition of subsequent changes in fair value through the results of operations.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(5) Fair Value of Financial Instruments The Company follows FASB accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows: • Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities • Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability • Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity) The Company has classified assets and liabilities measured at fair value on a recurring basis as follows: Fair value measurements at reporting date using Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) At December 31, 2016: Assets: Money market mutual funds $ 37,079 $ — $ — U.S. Government and agency bonds 20,517 — — Cash equivalents $ 57,596 $ — $ — Liabilities: Warrants — — $ 3,397 Contingent consideration — — 69,574 $ — $ — $ 72,971 At March 31, 2017: Assets: Cash equivalents Money market mutual funds $ 18,028 $ — $ — Total cash equivalents $ 18,028 $ — $ — Short-term investments U.S. Government and agency bonds $ 36,060 $ — $ — Total financial assets $ 54,088 $ — $ — Liabilities: Warrants — — $ 3,688 Contingent consideration — — 72,388 $ — $ — $ 76,076 The reconciliation of the contingent consideration and warrants measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrants Contingent Consideration Balance at December 31, 2016 $ 3,397 $ 69,574 Additions — — Remeasurement 291 2,814 Balance at March 31, 2017 $ 3,688 $ 72,388

Inventory

Inventory	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventory	(6) Inventory Inventory consists of the following: March 31, 2017 December 31, 2016 Raw materials $ 2,361 $ 2,557 Work in process 2,833 4,396 Finished goods 2,616 1,793 $ 7,810 $ 8,746

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	(7) Property, Plant and Equipment Property, plant and equipment consists of the following: March 31, 2017 December 31, 2016 Land $ 3,263 $ 3,263 Building and improvements 15,756 15,613 Furniture, office and computer equipment 3,973 3,811 Vehicles 30 30 Manufacturing equipment 22,832 21,508 Construction in Progress 1,742 2,198 47,596 46,423 Less: accumulated depreciation and amortization 10,319 9,123 Property, plant and equipment, net $ 37,277 $ 37,300 Depreciation expense for the three months ended March 31, 2017 and 2016 was $1,196 and $1,271.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	(8) Intangible Assets The following represents the balance of the intangible assets at March 31, 2017: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships: $ 15,500 $ 5,113 $ 10,387 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 5,113 $ 36,787 The following represents the balance of intangible assets at December 31, 2016: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships: $ 15,500 $ 4,467 $ 11,033 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 4,467 $ 37,433 Amortization expense for each of the three months ended March 31, 2017 and 2016 was $646. As of March 31, 2017, future amortization expense is as follows: Amortization April - December 2017 $ 1,937 2018 2,583 2019 2,583 2020 2,583 2021 701 Total $ 10,387

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2017
Payables And Accruals [Abstract]
Accrued Expenses	(9) Accrued Expenses Accrued expenses consist of the following: March 31, December 31, 2017 2016 Clinical trial and related costs $ 2,415 $ 2,564 Professional and consulting fees 604 360 Payroll and related costs 2,153 4,547 Property plant and equipment 201 720 Deferred revenue 796 418 Income tax payable 1,252 311 Other 716 973 $ 8,137 $ 9,893

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt	(10) Long-Term Debt The Company financed the Gainesville Transaction with cash on hand and a $50,000 five-year senior secured term loan, pursuant to a credit agreement, entered into on April 10, 2015, with OrbiMed Royalty Opportunities II, LP, or OrbiMed. The unpaid principal amount under the credit agreement is due and payable on April 10, 2020, the five-year anniversary of the loan provided thereunder by OrbiMed. The credit agreement also provides for certain mandatory prepayment events, including a quarterly excess cash flow prepayment requirement at OrbiMed’s request. The Company may make voluntary prepayments in whole or in part, subject to: (i) on or prior to the 36-month anniversary of the closing of the credit agreement, payment of a buy-out premium amount equal to (A) for full prepayments of the unpaid principal amount, $75,000 less all previously prepaid principal amounts and all previously paid interest or (B) for partial prepayments of the unpaid principal amount, 0.5 times the partial prepayment amount less interest payments previously paid in respect to the partial prepayment amount and (ii) after the 36-month anniversary of the closing of the credit agreement, payment of an exit fee amount equal to 10% of the amount of any prepayments. As defined by the agreement, based upon the CDMO segment financial results, OrbiMed has the option to require the Company to prepay a portion of the loan balance based upon an Excess Cash Flow. No payments under this option shall be subject to the buy-out premium. As of March 31, 2017, the Company has paid $22,653 of principal payments on the senior secured loan from the Excess Cash Flow calculation. The credit agreement carries interest at three month LIBOR plus 14.0% with a 1.0% floor. The Company’s obligations under the senior term loan are secured by substantially all of the Company’s assets. The credit agreement contains certain usual and customary affirmative and negative covenants, as well as financial covenants that the Company will need to satisfy on a monthly and quarterly basis. As of March 31, 2017, the Company was in compliance with the covenants. The Company issued to OrbiMed a warrant to purchase 294,928 shares of common stock, with an exercise price of $3.28 per share. The warrant is exercisable through April 10, 2022. The initial fair value of the warrant of $2,861 was recorded as debt issuance costs. Debt issuance costs related to the term loan of $4,579, including the initial warrant fair value of $2,861, are being amortized to interest expense over the five-year term of the loan and netted with the loan principal amount. The unamortized balance of debt issuance costs is $2,801 as of March 31, 2017. As of March 31, 2017, the long-term debt balance is comprised of the following: Principal balance outstanding $ 27,347 Unamortized deferred issuance costs (2,801 ) $ 24,546 Current portion (1,851 ) $ 22,695 The Company has estimated the amount of the Excess Cash Flow payments that could be payable within one year of March 31, 2017 upon request of OrbiMed and has classified that amount as a current debt in the accompanying consolidated balance sheet.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(11) Commitments and Contingencies (a) License and Supply Agreements In August 2008, the Company entered into a License Agreement with Orion Corporation (Orion) for Non-Injectable Dexmedetomidine. Under the Dexmedetomidine License Agreement, the Company was granted an exclusive license under the Orion Know-How and Cygnus/Farmos Patent to commercialize products in the territory, as defined in such agreement, and to use, research, develop and manufacture products worldwide, except for Europe, Turkey and the CIS (currently includes Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan), referred to herein as the Territory, and to use, research, develop and manufacture products worldwide solely for purposes of commercialization. The Company also entered into a supply agreement with Orion in which Orion will supply the Company with Dexmedetomidine at no cost during the product development period, and, upon United States Food and Drug Administration, or FDA, approval, Orion will supply commercial quantities of bulk active pharmaceutical ingredient Dexmedetomidine for commercialization. The Company will pay up to €20,500 ($21.9 million as of March 31, 2017) in contingent milestones upon the achievement of certain regulatory and commercialization events. There are also royalty payments to be paid at varying percentages of net sales, which generally range from 10% to 20% depending on annual sales levels. No amounts were due or payable during 2017 or 2016. In July 2010, the Company entered into a License Agreement with Orion for Fadolmidine. Under the Fadolmidine License Agreement, the Company was granted an exclusive license under the Orion Know-How and Orion Patent Rights (each as defined in the License Agreement) to commercialize products in the territory, as defined in such agreement, and to use, research, develop and manufacture products worldwide solely for purposes of commercialization. The Company will pay up to an additional €12,200 ($13.1 million as of March 31, 2017) in contingent milestones upon the achievement of certain regulatory and commercialization events. There are also royalty payments to be paid at varying percentages, which range from 10% to 15% of net sales. No amounts were due or payable during 2017 or 2016. As of March 31, 2017, the Company had $4,866 of non-cancellable commitments at our CDMO segment facility for capital expenditures and material and services. (b) Agreements with Alkermes Pursuant to the purchase and sale agreement governing the Gainesville Transaction, the Company agreed to pay to Alkermes up to an additional $125.0 million in milestone payments (including, at the Company’s election, either (i) $10 million upon NDA filing and $30 million upon regulatory approval or (ii) an aggregate of $45 million upon regulatory approval, as well as net sales milestones related to injectable meloxicam and royalties on future product sales of injectable meloxicam between 10% and 12% (subject to a 30% reduction when no longer covered by patent). The Company also entered into a Development, Manufacturing and Supply Agreement, or Supply Agreement, with Alkermes (through a subsidiary of Alkermes), pursuant to which Alkermes will (i) provide clinical and commercial bulk supplies of injectable meloxicam formulation and (ii) provide development services with respect to the Chemistry, Manufacturing and Controls section of an NDA for injectable meloxicam. Pursuant to the Supply Agreement, Alkermes will supply the Company with such quantities of bulk injectable meloxicam formulation as shall be reasonably required for the completion of clinical trials of injectable meloxicam. During the term of the Supply Agreement, the Company will purchase its clinical and commercial supplies of bulk injectable meloxicam formulation exclusively from Alkermes, subject to certain exceptions, for a period of time. (c) Litigation The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. Except as disclosed below, the Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition or results of operations. As part of the Gainesville Transaction, the Company acquired the rights to Zohydro ER®, which the Company licenses to its commercial partner, Pernix Therapeutics Holdings, Inc., or Pernix, in the United States, and which is subject to ongoing intellectual property litigation and proceedings. Zohydro ER® is subject to six paragraph IV certifications, two of which were filed in 2014 by Actavis plc, or Actavis, and Alvogen Pine Brook, Inc., or Alvogen, regarding the filing of Abbreviated NDAs, or ANDAs, with the FDA for a generic version of Zohydro ER®, one of which was filed in April 2015 by Actavis regarding the filing of a supplemental ANDA, or sANDA, and another three of which were filed in November 2015 and October 2016 by Actavis, and in December 2015 by Alvogen regarding one of our recently issued patents relating to a formulation of Zohydro ER®. These certification notices allege that three U.S. patents listed in the FDA’s Orange Book for Zohydro ER®, with an expiration date of November 2019 and September 2034, will not be infringed by Actavis’ or Alvogen’s proposed products, are invalid and/or are unenforceable. In 2014, Davrata Limited (a subsidiary of Alkermes and the Company’s predecessor in interest) filed suit against each of Actavis and Alvogen in the U.S. District Court for the District of Delaware based on the ANDAs, and in 2015, the Company filed suit against Actavis in the U.S. District Court for the District of Delaware based on the sANDA. In addition, in April 2015, the U.S. Patent and Trademark Office, or the USPTO, declared an interference between one of the Company’s patent applications relating to a dosage form of Zohydro ER® and two Purdue Pharma, LP, or Purdue, applications. On April 29, 2016, the USPTO found the Company’s claims and the Purdue claims involved in the interference to be invalid. Purdue appealed this decision to the U.S. Court of Appeals for the Federal Circuit on June 28, 2016. Under the Company’s license agreement with Pernix, the Company has the right to control the enforcement of the Company’s patents and related proceedings involving Zohydro ER® and any prospective generic entrant, and Pernix has the obligation to reimburse the Company for all reasonable costs of paragraph IV certification actions. On September 29, 2016, the Company entered into a settlement agreement with Alvogen pursuant to which the case against Alvogen was dismissed. In February 2017, the District Court in the Actavis case ruled in the Company’s favor and enjoined Actavis from selling the proposed generic version of Zohydro ER®. Actavis has appealed this decision to the U.S. Court of Appeals for the Federal Circuit. (d) Leases On January 1, 2017, the Company entered into a six-year lease for the Malvern facility that expires on December 31, 2022. In April 2017, the Company also entered into a three-year lease for office space in Dublin, Ireland that expires April 2020. Rent expense includes rent as well as additional operating and tenant improvement expenses. As of March 31, 2017, future minimum lease payments (including our Dublin lease) excluding operating expenses and tenant improvements for the leases, are as follows: Lease payments 2017 $ 312 2018 496 2019 507 2020 395 2021 362 2022 373 Total $ 2,445

Capital Structure

Capital Structure	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Capital Structure	(12) Capital Structure (a) Common Stock The Company is authorized to issue 50,000,000 shares of common stock, with a par value of $0.01 per share. On March 12, 2014, the Company completed an initial public offering, or IPO, in which the Company sold 4,312,500 shares of common stock at $8.00 per share, resulting in gross proceeds of $34,500. In connection with the IPO, the Company paid $4,244 in underwriting discounts, commissions and offering costs, resulting in net proceeds of $30,256. Also in connection with the IPO, all of the outstanding shares of the Company’s Series A Redeemable Convertible Preferred Stock, including accreted dividends, and Bridge Notes, including accrued interest, were converted into common stock. On July 7, 2015, the Company closed a private placement with certain accredited investors in which the Company sold 1,379,311 shares of common stock at a price of $11.60 per share, for net proceeds of $14,812. The Company paid the placement agents a fee equal to 6.0% of the aggregate gross proceeds from the private placement, plus reimbursement of certain expenses. On August 19, 2016, the Company closed an underwritten public offering in which the company sold 1,986,666 shares of common stock at a price per share of $7.50, for net proceeds of $13,367 after deducting underwriting commissions and offering expenses. On December 16, 2016, the Company closed an underwritten public offering in which the company sold 6,670,000 shares of common stock at a price per share of $6.00, for net proceeds of $36,888 after deducting underwriting commissions and offering expenses. (b) Common Stock Purchase Agreement On February 2, 2015, the Company entered into a Common Stock Purchase Agreement, or the Purchase Agreement, with Aspire Capital Fund, LLC, or Aspire Capital, pursuant to which Aspire Capital was committed to purchase, at the Company’s election, up to an aggregate of $10,000 of shares of the Company’s common stock over the 24-month term of the Purchase Agreement. On the execution of the Purchase Agreement, the Company issued 96,463 shares of common stock to Aspire Capital with a fair value of $285, as consideration for entering in the Purchase Agreement. In addition, the Company incurred $253 of costs in connection with the Aspire Capital facility, which, along with the fair value of the common stock, has been recorded as deferred equity costs. During 2016, the Company sold 1,143,940 shares of common stock under the Purchase Agreement for $7,796. The agreement expired in February 2017. (c) Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.01 per share. As of March 31, 2017, no preferred stock was issued or outstanding. (d) Warrants As of March 31, 2017, the Company had the following warrants outstanding to purchase shares of the Company’s common stock: Number of Shares Exercise Price per Share Expiration Date 140,000 $ 12.00 March 2018 350,000 $ 19.46 April 2022 294,928 $ 3.28 April 2022 The warrant to purchase 350,000 shares is liability classified since it contains a contingent net cash settlement feature. The warrant to purchase 294,928 shares is liability classified since it contains an anti-dilution provision. The fair value of both warrants will be remeasured through settlement or expiration with changes in fair value recognized as a period charge within the statement of operations.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	(13) Stock-Based Compensation The Company established the 2008 Stock Option Plan, or the 2008 Plan, which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors. As of March 31, 2017, no stock appreciation rights have been issued. Subsequent to adoption, the 2008 Plan was amended to increase the authorized number of shares available for grant to 444,000 shares of common stock. In October 2013, the Company established the 2013 Equity Incentive Plan, or the 2013 Plan, which allows for the grant of stock options, stock appreciation rights and stock awards for a total of 600,000 shares of common stock. In June 2015, the Company’s shareholders approved the Amended and Restated Equity Incentive Plan, or the A&R Plan, which amended and restated the 2013 Plan and increased the aggregate amount of shares available for issuance to 2,000,000. On December 1 st st Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of March 31, 2017, 479,874 shares and 174 shares are available for future grants under the A&R Plan and 2008 Plan, respectively. The weighted average grant-date fair value of the options awarded to employees during the three months ended March 31, 2017 and 2016 was $5.29 and $4.09, respectively. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following assumptions: March 31, 2017 2016 Range of expected option life 6 years 6 years Expected volatility 84.71% 74.82% Risk-free interest rate 2.05-2.17% 1.78-1.91% Expected dividend yield — — The following table summarizes stock option activity during the three months ended March 31, 2017: Number of shares Weighted average exercise price Weighted average remaining contractual life Balance, December 31, 2016 2,611,929 $ 7.01 Granted 509,500 7.36 Exercised — — Expired/forfeited/cancelled (21,768 ) 8.20 Balance, March 31, 2017 3,099,661 $ 7.06 7.6 years Vested 1,569,164 $ 6.52 6.2 years Vested and expected to vest 2,995,062 $ 7.02 7.6 years Included in the table above are 364,000 options granted outside the plan. The grants were made pursuant to the NASDAQ inducement grant exception in accordance with NASDAQ Listing Rule 5635(c)(4). The following table summarizes restricted stock units activity during the three months ended March 31, 2017. Number of shares Balance, December 31, 2016 7,750 Granted 238,550 Vested (7,750 ) Expired/forfeited/cancelled (750 ) Balance, March 31, 2017 237,800 Expected to vest 237,800 In January 2017, the Company granted 91,150 performance-based restricted stock units, or RSU’s, which vest based on attaining clinical and operational goals during 2017, as well as 147,400 time-based RSU’s, which vest over four years. Stock-based compensation expense for the three months ended March 31, 2017 and 2016 was $892 and $701, respectively. As of March 31, 2017, there was $10,693 of unrecognized compensation expense related to unvested options and RSUs that are expected to vest and will be expensed over a weighted average period of 2.9 years. The aggregate intrinsic value represents the total amount by which the fair value of the common stock subject to options exceeds the exercise price of the related options. As of March 31, 2017, the aggregate intrinsic value of the vested and unvested options was $3,953 and $2,336, respectively.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment Reporting	(14) Segment Reporting The Company operates through two business segments: an Acute Care segment and a revenue-generating CDMO segment. The Acute Care segment is primarily focused on developing innovative products for hospital and related settings, and the CDMO segment leverages the Company’s formulation expertise to develop and manufacture pharmaceutical products using the Company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Acute Care has no revenue, and its costs consist primarily of expenses incurred in conducting the Company’s clinical and preclinical studies, acquiring clinical trial materials, regulatory activities, personnel costs and pre-commercialization of meloxicam. CDMO revenue streams are derived from manufacturing, royalty and profit-sharing revenues, as well as CDMO’s research and development of services performed for commercial partners. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 3). The Company evaluates performance of its reportable segments based on revenue and operating income (loss). The Company does not allocate interest income, interest expense or income taxes to its operating segments. The following table summarizes segment information as of and for the three months ended March 31, 2017 and 2016: For the Three Months Ended March 31, 2017 2016 Revenues: CDMO $ 18,742 $ 17,742 Acute Care — — Total $ 18,742 $ 17,742 Operating income (loss): CDMO $ 6,199 $ 5,644 Acute Care (13,501 ) (10,669 ) Total $ (7,302 ) $ (5,025 ) Depreciation and amortization: CDMO $ 1,837 $ 1,917 Acute Care 5 — Total $ 1,842 $ 1,917 Capital expenditures: CDMO $ 1,530 $ 344 Acute Care 214 — Total $ 1,744 $ 344 March 31, December 31, 2017 2016 Total assets: CDMO $ 75,588 $ 77,828 Acute Care 100,486 105,169 Total $ 176,074 $ 182,997

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	(15) Related Party Transactions The Company’s President and Chief Executive Officer, or CEO, owns a majority of the stock of Malvern Consulting Group, or MCG, a pharmaceutical incubator and consulting firm. The CEO’s husband, who is also a shareholder of the Company, is a consultant and a shareholder of MCG. In addition, the CEO’s son is the President and a shareholder of MCG. During 2016, certain immediate family members of the CEO were employees of MCG, including the CEO’s brother and sister-in-law. Since formation, the Company entered into various transactions with MCG, as detailed below. However, since becoming a public company, the Company sought to decrease its involvement with MCG, and, as of December 31, 2016, the Company no longer has any involvement or transactions with MCG. During 2016, certain of the Company’s executive officers, its CEO, its Senior Vice President, Development and its Senior Vice President, Regulatory Affairs and Quality Assurance, who is also the CEO's sister, provided minimal consulting services from time to time to MCG. Until December 31, 2016, the Company was a party to a Master Consulting Services Agreement with MCG. Pursuant to the agreement, MCG provided the Company with certain consulting services for a fee based upon hourly rates previously approved by the Company’s Board of Directors. In consideration for such services, the Company recorded $101 for the three months ended March 31, 2016. A portion of these amounts were used during 2016 to pay a portion of the respective salaries of MCG employees that, as described above, included immediate family members of the Company’s CEO. Until December 31, 2016, the Company was party to an Office Services Agreement with MCG for the lease of an aggregate of 8,458 square feet of office and lab space located at our Malvern facility and the provision of IT services and general office support. Pursuant to the Office Services Agreement, the Company paid MCG $51 in the three months ended March 31, 2016. The Company terminated this agreement on December 31, 2016 and is now a party to a six-year lease directly with the landlord of the Company’s Malvern facility (see Note 11). As of December 31, 2016, the Company has terminated the Master Consulting Agreement, the Office Services Agreement and MCG no longer provides any services or has any contracts with the Company. The Company’s Senior Vice President, Regulatory and Quality, who is the CEO’s sister, has held that position since 2014. Effective January 1, 2017, the CEO’s sister-in-law and brother, respectively, terminated their employment with MCG and were hired as the Company’s Director of Human Resources and our Vice President, Manufacturing. The Board approved these hires consistent with the Company’s related person transaction policy.

Summary of Significant Accoun22

Summary of Significant Accounting Principles (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	(a) Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of March 31, 2017 and its results of operations and cash flows for the three months ended March 31, 2017 and 2016. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The consolidated interim financial statements, presented herein, do not contain the required disclosures under U.S. GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
Use of Estimates	(b) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.
Cash, Cash Equivalents and Short-term Investments	(c) Cash, Cash Equivalents and Short-term Investments The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents as of March 31, 2017 and 2016 consisted of money market mutual funds and U.S. Government and agency bonds. Short-term investments consisted of U.S. Government and agency bonds with maturities of less than one year. The Company classifies all of its short-term investments as “available-for-sale.” In general, these investments are free of trading restrictions. The Company carries these investments at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses are included in accumulated other comprehensive loss, which is reflected as a separate component of shareholders’ equity in the Company’s consolidated balance sheets. Gains and losses are recognized when realized in the Company’s consolidated statements of income. When the Company has determined that an other-than-temporary decline in fair value has occurred, the amount of the decline that is related to a credit loss is recognized in income. Gains and losses are determined using the specific identification method.
Fair Value of Financial Instruments	(d) Fair Value of Financial Instruments Management believes that the carrying amounts of the Company’s financial instruments, including cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, approximate fair value due to the short-term nature of those instruments. Management believes the carrying value of debt approximates fair value as the interest rates are reflective of the rate the Company could obtain on debt with similar terms and conditions.
Inventory	(e) Inventory Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Included in inventory are raw materials used in production of commercial products.
Property and Equipment	(f) Property and Equipment Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture and office equipment; six to ten or more years for manufacturing equipment; two to five years for vehicles; 35 to 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance cost are expensed as incurred.
Goodwill and Intangible Assets	(g) Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized, but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment model prescribes a two-step method for determining impairment. The first step compares a reporting unit’s fair value to its carrying amount to identify potential goodwill impairment. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the second step of the impairment test must be completed to measure the amount of the reporting unit’s goodwill impairment loss, if any. Step two requires an assignment of the reporting unit’s fair value to the reporting unit’s assets and liabilities to determine the implied fair value of the reporting unit’s goodwill. The implied fair value of the reporting unit’s goodwill is then compared with the carrying amount of the reporting unit’s goodwill to determine the goodwill impairment loss to be recognized, if any. Intangible assets include the Company’s royalties and contract manufacturing relationships intangible asset as well as an in-process research and development, or IPR&D, asset. The royalties and contract manufacturing relationships intangible asset is considered a definite-lived intangible asset and is amortized on a straight-line basis over a useful life of six years. Intangible assets related to IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off, and the Company will record a noncash impairment loss on its consolidated statements of operations. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. The impairment test for indefinite-lived intangible assets is a one-step test, which compares the fair value of the intangible asset to its carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to the excess. Based on accounting standards, it is required that these assets be assessed at least annually for impairment unless a triggering event occurs between annual assessments, which would then require an assessment in the period which a triggering event occurred.
Revenue Recognition	(h) Revenue Recognition The Company generates revenues from manufacturing, packaging and related services for multiple pharmaceutical companies. The agreements that the Company has with its commercial partners provide for manufacturing revenues, royalties and/or profit sharing components. Manufacturing and other related services revenue is recognized when persuasive evidence of an arrangement exists, shipment has occurred and the title to the product and associated risk of loss has passed to the customer, the sales price is fixed or determinable and collectability is reasonably assured. In addition to manufacturing and packaging revenue, the customer agreements have royalties and/or profit sharing payments, computed on the net product sales of the partner. Royalty and profit sharing revenues are generally recognized under the terms of the license and supply agreement in the period the products are sold and expenses are incurred by the Company’s CDMO commercial partner and when collectability is reasonably assured. Revenues related to research and development are generally recognized as the related services or activities are performed, in accordance with the contract terms. To the extent that the agreements specify services are to be performed on a fixed basis, revenues are recognized consistent with the pattern of the work performed. In agreements which specify milestones, the related revenues are recognized upon the achievement of a substantive milestone.
Concentration of Credit Risk	(i) Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company’s policy is to limit the amount of credit exposure to any one financial institution and place its cash and cash equivalents with financial institutions evaluated as being creditworthy. To date, the Company has not experienced any losses on its cash equivalents.
Research and Development	(j) Research and Development Research and development costs for the Company’s proprietary products/product candidates are charged to expense as incurred. Research and development expenses consist primarily of funds paid to third parties for the provision of services for manufacturing of clinical supplies, drug development, clinical trials, statistical analysis and report writing and regulatory compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expenses relating to these costs. Upfront and milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired IPR&D if the technology licensed has not reached technological feasibility and has no alternative future use.
Stock-Based Awards	(k) Stock-Based Awards The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of options grants. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Non-employee stock-based awards are revalued until an award vests and the Company recognizes compensation expense on a straight-line basis over the vesting period of each separated vesting tranche of the award, which is known as the accelerated attribution method. The estimation of the number of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company’s current estimates, such amounts are recognized as an adjustment in the period in which estimates are revised.
Income Taxes	(l) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company accrues interest, and related penalties are classified as income tax expense in the Consolidated Statements of Operations. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year.
Net Loss Per Common Share	(m) Net Loss Per Common Share Basic net loss per common share is determined by dividing net loss by the weighted average common shares outstanding during the period. For all periods presented, the outstanding common stock options, unvested restricted stock units and warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of March 31, 2017 and 2016, as they would be anti-dilutive: March 31, 2017 2016 Options and restricted stock units outstanding 3,337,461 2,224,123 Warrants 784,928 784,928 Amounts in the table above reflect the common stock equivalents of the noted instruments.
Segment Information	(n) Segment Information The Company determined its reportable segments based on its strategic business units, the commonalities among the products and services within each segment and the manner in which the Company reviews and evaluates operating performance. The Company has identified CDMO and Acute Care as reportable segments. Segment disclosures are included in Note 14. Segment operating profit (loss) is defined as segment revenue less segment operating expenses (segment operating expenses consist of general and administrative expenses, research and development expenses, and the change in valuation of contingent consideration and warrants). The following items are excluded from segment operating profit (loss): interest income and expense, and income tax benefit (expense). Segment assets are those assets and liabilities that are recorded and reported by segment operations. Segment operating capital employed represents segment assets less segment liabilities.
Recent Accounting Pronouncements	(o) Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board, or FASB, issued updated guidance on the annual goodwill impairment test. The amended guidance allows companies to apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit’s carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The amendments of the Accounting Standards Update, or ASU, are effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the effect that this guidance may have on its consolidated financial statements. In August 2016, the FASB issued updated guidance in the classification of certain cash receipts and payments in the statement of cash flows where diversity in practice exists. This new guidance is effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In March 2016, the FASB issued updated guidance on the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, employee tax withholding, calculation of shares for use in diluted earnings per share and the classification on the statement of cash flows. The new guidance is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company early adopted the guidance effective July 1, 2016. The guidance did not have a material impact to the consolidated financial statements upon adoption. In February 2016, the FASB issued updated guidance regarding the accounting for and disclosures of leases. This new ASU represents a wholesale change to lease accounting and introduces a lease model that brings most leases on the balance sheet. It also eliminates the required use of bright-line tests in current U.S. GAAP for determining lease classification. The new guidance is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect that this guidance may have on its consolidated financial statements. In September 2015, the FASB issued updated guidance regarding the accounting for and disclosure of measurement-period adjustments that occur in periods after a business combination is consummated. This update requires that the acquirer recognize measurement-period adjustments in the reporting period in which they are determined. Prior period information should not be revised. This update also requires an entity to present separately on the face of the income statement or disclose in the notes the amount recorded in the current-period income statement that would have been recorded in previous reporting periods if the adjustments had been recognized as of the acquisition date. The updated guidance is effective for annual and interim periods beginning after December 15, 2016. The Company adopted the guidance effective January 1, 2017. The guidance did not have a material impact to the consolidated financial satements upon adoption. In July 2015, the FASB issued updated guidance which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. The amendments in this guidance do not apply to inventory that is measured using last-in, first-out, or LIFO, or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. Within the scope of this new guidance, an entity should measure inventory at the lower of cost and net realizable value; where net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The new guidance is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The new guidance must be applied on a prospective basis. The Company adopted the guidance effective January 1, 2017. The guidance did not have a material impact to the consolidated financial satements upon adoption. In May 2014, the FASB issued updated guidance regarding the accounting for and disclosures of revenue recognition, with an effective date for annual and interim periods beginning after December 15, 2016. The update provides a single comprehensive model for accounting for revenue from contracts with customers. The model requires that revenue recognized reflect the actual consideration to which the entity expects to be entitled in exchange for the goods or services defined in the contract, including in situations with multiple performance obligations. In July 2015, the FASB deferred the effective date by one year. The guidance will be effective for annual and interim periods beginning after December 15, 2017. The new standard permits two methods of adoption: the full retrospective method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company currently anticipates adopting the standard using the modified retrospective method. The Company plans to complete an analysis of existing contracts with its customers and to assess the differences in accounting for such contracts under ASU 2014-09 compared with current revenue accounting standards by the end of the third quarter. The new standard will result in additional revenue-related disclosures in the footnotes to the consolidated financial statements. The Company will continue to assess new customer contracts during 2017. Adoption of this standard will require changes to business processes, systems and controls to support the additional required disclosures. The Company is in the process of identifying such changes.

Summary of Significant Accoun23

Summary of Significant Accounting Principles (Tables)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Schedule of Anti-Dilutive Securities	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of March 31, 2017 and 2016, as they would be anti-dilutive: March 31, 2017 2016 Options and restricted stock units outstanding 3,337,461 2,224,123 Warrants 784,928 784,928

Fair Value of Financial Instr24

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Classification of Assets and Liabilities Measured at Fair Value on Recurring Basis	The Company has classified assets and liabilities measured at fair value on a recurring basis as follows: Fair value measurements at reporting date using Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) At December 31, 2016: Assets: Money market mutual funds $ 37,079 $ — $ — U.S. Government and agency bonds 20,517 — — Cash equivalents $ 57,596 $ — $ — Liabilities: Warrants — — $ 3,397 Contingent consideration — — 69,574 $ — $ — $ 72,971 At March 31, 2017: Assets: Cash equivalents Money market mutual funds $ 18,028 $ — $ — Total cash equivalents $ 18,028 $ — $ — Short-term investments U.S. Government and agency bonds $ 36,060 $ — $ — Total financial assets $ 54,088 $ — $ — Liabilities: Warrants — — $ 3,688 Contingent consideration — — 72,388 $ — $ — $ 76,076
Reconciliation of Contingent Consideration and Warrants Measured at Fair Value on Recurring Basis Using Unobservable Inputs	The reconciliation of the contingent consideration and warrants measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrants Contingent Consideration Balance at December 31, 2016 $ 3,397 $ 69,574 Additions — — Remeasurement 291 2,814 Balance at March 31, 2017 $ 3,688 $ 72,388

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Components of Inventory	Inventory consists of the following: March 31, 2017 December 31, 2016 Raw materials $ 2,361 $ 2,557 Work in process 2,833 4,396 Finished goods 2,616 1,793 $ 7,810 $ 8,746

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Schedule of Fair Value of Property, Plant and Equipment and Their Weighted-Average Useful Lives	Property, plant and equipment consists of the following: March 31, 2017 December 31, 2016 Land $ 3,263 $ 3,263 Building and improvements 15,756 15,613 Furniture, office and computer equipment 3,973 3,811 Vehicles 30 30 Manufacturing equipment 22,832 21,508 Construction in Progress 1,742 2,198 47,596 46,423 Less: accumulated depreciation and amortization 10,319 9,123 Property, plant and equipment, net $ 37,277 $ 37,300

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Balance of Intangible Assets	The following represents the balance of the intangible assets at March 31, 2017: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships: $ 15,500 $ 5,113 $ 10,387 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 5,113 $ 36,787 The following represents the balance of intangible assets at December 31, 2016: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships: $ 15,500 $ 4,467 $ 11,033 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 4,467 $ 37,433
Schedule of Future Amortization Expense	As of March 31, 2017, future amortization expense is as follows: Amortization April - December 2017 $ 1,937 2018 2,583 2019 2,583 2020 2,583 2021 701 Total $ 10,387

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2017
Payables And Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consist of the following: March 31, December 31, 2017 2016 Clinical trial and related costs $ 2,415 $ 2,564 Professional and consulting fees 604 360 Payroll and related costs 2,153 4,547 Property plant and equipment 201 720 Deferred revenue 796 418 Income tax payable 1,252 311 Other 716 973 $ 8,137 $ 9,893

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Balance	As of March 31, 2017, the long-term debt balance is comprised of the following: Principal balance outstanding $ 27,347 Unamortized deferred issuance costs (2,801 ) $ 24,546 Current portion (1,851 ) $ 22,695

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments (Including Dublin Lease) Excluding Operating Expenses and Tenant Improvements	As of March 31, 2017, future minimum lease payments (including our Dublin lease) excluding operating expenses and tenant improvements for the leases, are as follows: Lease payments 2017 $ 312 2018 496 2019 507 2020 395 2021 362 2022 373 Total $ 2,445

Capital Structure (Tables)

Capital Structure (Tables)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Schedule of Warrants Outstanding to Purchase Shares of Common Stock	As of March 31, 2017, the Company had the following warrants outstanding to purchase shares of the Company’s common stock: Number of Shares Exercise Price per Share Expiration Date 140,000 $ 12.00 March 2018 350,000 $ 19.46 April 2022 294,928 $ 3.28 April 2022

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model	The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following assumptions: March 31, 2017 2016 Range of expected option life 6 years 6 years Expected volatility 84.71% 74.82% Risk-free interest rate 2.05-2.17% 1.78-1.91% Expected dividend yield — —
Summary of Stock Option Activity	The following table summarizes stock option activity during the three months ended March 31, 2017: Number of shares Weighted average exercise price Weighted average remaining contractual life Balance, December 31, 2016 2,611,929 $ 7.01 Granted 509,500 7.36 Exercised — — Expired/forfeited/cancelled (21,768 ) 8.20 Balance, March 31, 2017 3,099,661 $ 7.06 7.6 years Vested 1,569,164 $ 6.52 6.2 years Vested and expected to vest 2,995,062 $ 7.02 7.6 years
Summary of Restricted Stock Units Activity	The following table summarizes restricted stock units activity during the three months ended March 31, 2017. Number of shares Balance, December 31, 2016 7,750 Granted 238,550 Vested (7,750 ) Expired/forfeited/cancelled (750 ) Balance, March 31, 2017 237,800 Expected to vest 237,800

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Summary of Segment Information	The following table summarizes segment information as of and for the three months ended March 31, 2017 and 2016: For the Three Months Ended March 31, 2017 2016 Revenues: CDMO $ 18,742 $ 17,742 Acute Care — — Total $ 18,742 $ 17,742 Operating income (loss): CDMO $ 6,199 $ 5,644 Acute Care (13,501 ) (10,669 ) Total $ (7,302 ) $ (5,025 ) Depreciation and amortization: CDMO $ 1,837 $ 1,917 Acute Care 5 — Total $ 1,842 $ 1,917 Capital expenditures: CDMO $ 1,530 $ 344 Acute Care 214 — Total $ 1,744 $ 344 March 31, December 31, 2017 2016 Total assets: CDMO $ 75,588 $ 77,828 Acute Care 100,486 105,169 Total $ 176,074 $ 182,997

Background - Additional Informa

Background - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Entity incorporation date	Nov. 15, 2007
Number of operating divisions	2

Development-Stage Risks and L35

Development-Stage Risks and Liquidity - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Business Developments Risks And Uncertainties Liquidity [Abstract]
Accumulated deficit	$ 69,355	$ 61,268

Summary of Significant Accoun36

Summary of Significant Accounting Principles - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017
Royalties and Contract Manufacturing [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Definite-lived intangible asset, useful lives	6 years
Furniture and Office Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	3 years
Furniture and Office Equipment [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	10 years
Manufacturing Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	6 years
Manufacturing Equipment [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment useful life	ten or more years
Vehicles [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	2 years
Vehicles [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	5 years
Buildings [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	35 years
Buildings [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	40 years
Leasehold Improvements [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment useful life	the shorter of the lease term or useful life

Summary of Significant Accoun37

Summary of Significant Accounting Principles - Schedule of Anti-Dilutive Securities (Detail) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Options [Member] | Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	3,337,461	2,224,123
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	784,928	784,928

Acquisition of Gainesville Fa38

Acquisition of Gainesville Facility and Meloxicam - Additional Information (Detail) - Gainesville [Member] $ / shares in Units, $ in Millions	Apr. 10, 2015USD ($)$ / sharesshares
Business Acquisition [Line Items]
Business acquisition upfront payment in cash	$ 50
Working capital adjustment	4
Business acquisition contingent consideration possible milestone payments	$ 125
Maximum future net product sales milestone percentage	30.00%
Minimum [Member]
Business Acquisition [Line Items]
Future net product sales milestone percentage	10.00%
Maximum [Member]
Business Acquisition [Line Items]
Future net product sales milestone percentage	12.00%
NDA [Member]
Business Acquisition [Line Items]
Business acquisition contingent consideration possible milestone payments	$ 10
Regulatory Approval [Member]
Business Acquisition [Line Items]
Business acquisition contingent consideration possible milestone payments	30
Regulatory Approval and Net Sales Milestones [Member]
Business Acquisition [Line Items]
Business acquisition contingent consideration possible milestone payments	$ 45
Seven Year Warrant [Member]
Business Acquisition [Line Items]
Purchase common stock with warrant issue | shares	350,000
Warrant, exercise price per share | $ / shares	$ 19.46

Fair Value of Financial Instr39

Fair Value of Financial Instruments - Classification of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Fair value of total financial assets, recurring basis	$ 54,088
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money Market Mutual Funds [Member]
Assets:
Fair value of total financial assets, recurring basis	18,028	$ 37,079
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | U.S. Government and Agency Bonds [Member]
Assets:
Fair value of total financial assets, recurring basis		20,517
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | U.S. Government and Agency Bonds [Member] | Short-term Investments [Member]
Assets:
Fair value of total financial assets, recurring basis	36,060
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Cash Equivalents [Member]
Assets:
Fair value of total financial assets, recurring basis	18,028	57,596
Significant Unobservable Inputs (Level 3) [Member]
Liabilities:
Fair value of liabilities, recurring basis	76,076	72,971
Significant Unobservable Inputs (Level 3) [Member] | Warrants [Member]
Liabilities:
Fair value of liabilities, recurring basis	3,688	3,397
Significant Unobservable Inputs (Level 3) [Member] | Contingent Consideration [Member]
Liabilities:
Fair value of liabilities, recurring basis	$ 72,388	$ 69,574

Fair Value of Financial Instr40

Fair Value of Financial Instruments - Reconciliation of Contingent Consideration and Warrants Measured at Fair Value on Recurring Basis Using Unobservable Inputs (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Warrants [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Balance at December 31, 2016	$ 3,397
Remeasurement	291
Balance at March 31, 2017	3,688
Contingent Consideration [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Balance at December 31, 2016	69,574
Remeasurement	2,814
Balance at March 31, 2017	$ 72,388

Inventory - Components of Inven

Inventory - Components of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 2,361	$ 2,557
Work in process	2,833	4,396
Finished goods	2,616	1,793
Inventory	$ 7,810	$ 8,746

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 47,596	$ 46,423
Less: accumulated depreciation and amortization	10,319	9,123
Property, plant and equipment, net	37,277	37,300
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,263	3,263
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	15,756	15,613
Furniture, Office & Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,973	3,811
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	30	30
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	22,832	21,508
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,742	$ 2,198

Property, Plant and Equipment43

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation expense	$ 1,196	$ 1,271

Intangible Assets - Summary of

Intangible Assets - Summary of Balance of Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Cost, Total	$ 41,900	$ 41,900
Accumulated Amortization	5,113	4,467
Net Intangible Assets, Total	36,787	37,433
Royalties and Contract Manufacturing [Member]
Finite-Lived Intangible Assets [Line Items]
Cost, Definite-lived	15,500	15,500
Accumulated Amortization	5,113	4,467
Net Intangible Assets, Definite-lived	10,387	11,033
In-Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Indefinite-lived	$ 26,400	$ 26,400

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Intangible Assets Net Excluding Goodwill [Abstract]
Amortization expense	$ 646	$ 646

Intangible Assets - Summary o46

Intangible Assets - Summary of Future Amortization Expense (Detail) - Royalties and Contract Manufacturing [Member] - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
April - December 2017	$ 1,937
2,018	2,583
2,019	2,583
2,020	2,583
2,021	701
Total	$ 10,387	$ 11,033

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Clinical trial and related costs	$ 2,415	$ 2,564
Professional and consulting fees	604	360
Payroll and related costs	2,153	4,547
Property plant and equipment	201	720
Deferred revenue	796	418
Income tax payable	1,252	311
Other	716	973
Total accrued expenses	$ 8,137	$ 9,893

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Principal payments of senior secured loan, excess of cash flow calculation		$ 2,633
Unamortized balance of debt issuance costs	$ 2,801
OrbiMed [Member] | Seven Year Warrant [Member]
Debt Instrument [Line Items]
Purchase common stock with warrant issue	294,928
Warrant, exercise price per share	$ 3.28
Warrants, exercisable date	Apr. 10, 2022
OrbiMed Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Debt issuance costs related to term loan	$ 4,579
Unamortized balance of debt issuance costs	2,801
OrbiMed Senior Secured Term Loan [Member] | Warrants [Member]
Debt Instrument [Line Items]
Initial warrant fair value	2,861
OrbiMed Senior Secured Term Loan [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Term loan face amount	$ 50,000
Term loan maturity term	5 years
Term loan interest rate, Description	Interest at three month LIBOR plus 14.0% with a 1.0% floor
Term loan agreement date	Apr. 10, 2015
Term loan payable date	Apr. 10, 2020
Credit agreement prepayment terms	The Company may make voluntary prepayments in whole or in part, subject to: (i) on or prior to the 36-month anniversary of the closing of the credit agreement, payment of a buy-out premium amount equal to (A) for full prepayments of the unpaid principal amount, $75,000 less all previously prepaid principal amounts and all previously paid interest or (B) for partial prepayments of the unpaid principal amount, 0.5 times the partial prepayment amount less interest payments previously paid in respect to the partial prepayment amount and (ii) after the 36-month anniversary of the closing of the credit agreement, payment of an exit fee amount equal to 10% of the amount of any prepayments.
Credit agreement unpaid principal amount	$ 75,000
Exit fee percentage	10.00%
Principal payments of senior secured loan, excess of cash flow calculation	$ 22,653
OrbiMed Senior Secured Term Loan [Member] | Term Loan [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Term loan variable interest rate	14.00%
OrbiMed Senior Secured Term Loan [Member] | Term Loan [Member] | Floor [Member]
Debt Instrument [Line Items]
Term loan variable interest rate	1.00%

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt Balance (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Principal balance outstanding	$ 27,347
Unamortized deferred issuance costs	(2,801)
Long-term debt	24,546
Long-term debt:
Current portion	(1,851)	$ (2,236)
Long-term debt, non current	$ 22,695	$ 22,152

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jan. 02, 2017	Apr. 30, 2017	Mar. 31, 2017USD ($)	Mar. 31, 2017EUR (€)	Dec. 31, 2016USD ($)
Subsequent Event [Member] | Dublin [Member]
Supply Commitment [Line Items]
Lease commenced date		Apr. 16, 2017
Lease expiration date		Apr. 16, 2020
Term of contract		3 years
Malvern Consulting Group, Inc. (MCG) [Member]
Supply Commitment [Line Items]
Lease commenced date			Jan. 1, 2017	Jan. 1, 2017
Lease expiration date			Dec. 31, 2022	Dec. 31, 2022
Term of contract	6 years		6 years	6 years
Gainesville Transaction [Member]
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones			$ 125,000,000
Maximum future net product sales milestone percentage			30.00%	30.00%
Gainesville Transaction [Member] | NDA [Member]
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones			$ 10,000,000
Gainesville Transaction [Member] | Regulatory Approval [Member]
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones			30,000,000
Gainesville Transaction [Member] | Regulatory Approval and Net Sales Milestones [Member]
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones			45,000,000
CDMO [Member]
Supply Commitment [Line Items]
Non-cancellable commitments to be paid on capital expenditures, material and services			$ 4,866,000
Minimum [Member] | Gainesville Transaction [Member]
Supply Commitment [Line Items]
Future net product sales milestone percentage			10.00%	10.00%
Maximum [Member] | Gainesville Transaction [Member]
Supply Commitment [Line Items]
Future net product sales milestone percentage			12.00%	12.00%
Dexmedetomidine License Agreement [Member]
Supply Commitment [Line Items]
Contingent milestone payments, maximum			$ 21,900,000	€ 20,500,000
Amount of royalty payments due or payable			$ 0		$ 0
Dexmedetomidine License Agreement [Member] | Minimum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments			10.00%	10.00%
Dexmedetomidine License Agreement [Member] | Maximum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments			20.00%	20.00%
Fadolmidine License Agreement [Member]
Supply Commitment [Line Items]
Amount of royalty payments due or payable			$ 0		$ 0
Additional contingent milestones payment			$ 13,100,000	€ 12,200,000
Fadolmidine License Agreement [Member] | Minimum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments			10.00%	10.00%
Fadolmidine License Agreement [Member] | Maximum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments			15.00%	15.00%

Commitments and Contingencies51

Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Including Dublin Lease) Excluding Operating Expenses and Tenant Improvements (Detail) $ in Thousands	Mar. 31, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,017	$ 312
2,018	496
2,019	507
2,020	395
2,021	362
2,022	373
Lease payments, Total	$ 2,445

Capital Structure - Additional

Capital Structure - Additional Information (Detail) - USD ($)	Dec. 16, 2016	Aug. 19, 2016	Jul. 07, 2015	Feb. 02, 2015	Mar. 12, 2014	Mar. 31, 2016	Dec. 31, 2016	Mar. 31, 2017
Schedule Of Capitalization Equity [Line Items]
Common stock, shares authorized to issue							50,000,000	50,000,000
Common stock, par value							$ 0.01	$ 0.01
Aggregate net proceeds from private placement						$ 560,000
Preferred stock, shares authorized							10,000,000	10,000,000
Preferred stock, par value							$ 0.01	$ 0.01
Preferred stock, shares issued							0	0
Preferred stock, shares outstanding							0	0
Warrants, Exercise Price $19.46, Expiring on April 2022 [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares								350,000
Warrants, Exercise Price $19.46, Expiring on April 2022 [Member] | Liability Contingent Net Cash Settlement Feature [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares								350,000
Warrants, Exercise Price $3.28, Expiring on April 2022 [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares								294,928
Warrants, Exercise Price $3.28, Expiring on April 2022 [Member] | Liability Anti-Dilution Provision [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares								294,928
Aspire Capital [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance, shares				96,463			1,143,940
Common stock issuance							$ 7,796,000
Term of purchase agreement				24 months
Stock issued at fair value				$ 285,000
Cost incurred in stock issuance				$ 253,000
Common stock purchase agreement, expiration month and year				2017-02
Maximum [Member] | Aspire Capital [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance				$ 10,000,000
Investor [Member]
Schedule Of Capitalization Equity [Line Items]
Aggregate net proceeds from private placement			$ 14,812,000
Placement agents fee percentage			6.00%
Initial Public Offering (IPO) [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance, shares					4,312,500
Sale of stock, price per share					$ 8
Gross proceeds on sale of common stock in initial public offering					$ 34,500,000
Payments on underwriting discounts, commissions and offering costs					4,244,000
Common stock issuance					$ 30,256,000
Private Placement [Member] | Investor [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance, shares			1,379,311
Common stock issuance price			$ 11.60
Underwritten Public Offering [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance, shares	6,670,000	1,986,666
Common stock issuance price	$ 6	$ 7.50
Net proceeds from sale of common stock	$ 36,888,000	$ 13,367,000

Capital Structure - Schedule of

Capital Structure - Schedule of Warrants Outstanding to Purchase Shares of Common Stock (Detail)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Warrants, Exercise Price $12.00, Expiring on March 2018 [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding to purchase shares, Number of Shares | shares	140,000
Warrants outstanding to purchase shares, Exercise Price per Share | $ / shares	$ 12
Warrants outstanding to purchase shares, Expiration Date	2018-03
Warrants, Exercise Price $19.46, Expiring on April 2022 [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding to purchase shares, Number of Shares | shares	350,000
Warrants outstanding to purchase shares, Exercise Price per Share | $ / shares	$ 19.46
Warrants outstanding to purchase shares, Expiration Date	2022-04
Warrants, Exercise Price $3.28, Expiring on April 2022 [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding to purchase shares, Number of Shares | shares	294,928
Warrants outstanding to purchase shares, Exercise Price per Share | $ / shares	$ 3.28
Warrants outstanding to purchase shares, Expiration Date	2022-04

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended
	Jan. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2015	Oct. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable period				10 years
Stock options vest period				4 years
Weighted average grant-date fair value of the options awarded to employees				$ 5.29	$ 4.09
Stock-based compensation				$ 892	$ 701
Aggregate intrinsic value of vested options				3,953
Aggregate intrinsic value of unvested options				$ 2,336
Stock Options Granted Outside Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, Granted				364,000
Performance-based RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units granted	91,150			238,550
Unrecognized compensation expense related to unvested options, expected to vest				$ 10,693
Unrecognized compensation expense related to unvested options, weighted average period				2 years 10 months 24 days
Time Based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vest period	4 years
Number of restricted stock units granted	147,400
2008 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock appreciation rights issued in period				0
Additional number of shares authorized for grant				444,000
Shares available for future grants				174
2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant							600,000
A&R Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant				3,080,396		2,000,000
Increase in share per "Evergreen" provision		619,181	461,215
Percentage of outstanding common stock		5.00%
Shares available for future grants				479,874

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of expected option life	6 years	6 years
Expected volatility	84.71%	74.82%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.05%	1.78%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.17%	1.91%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of shares, beginning balance | shares	2,611,929
Number of shares, Granted | shares	509,500
Number of shares, Expired/forfeited/cancelled | shares	(21,768)
Number of shares, ending balance | shares	3,099,661
Number of shares, Vested | shares	1,569,164
Number of shares, Vested and expected to vest | shares	2,995,062
Weighted average exercise price, beginning balance | $ / shares	$ 7.01
Weighted average exercise price, Granted | $ / shares	7.36
Weighted average exercise price, Expired/forfeited/cancelled | $ / shares	8.20
Weighted average exercise price, ending balance | $ / shares	7.06
Weighted average exercise price, Vested | $ / shares	6.52
Weighted average exercise price, Vested and expected to vest | $ / shares	$ 7.02
Weighted average remaining contractual life	7 years 7 months 6 days
Weighted average remaining contractual life, Vested	6 years 2 months 12 days
Weighted average remaining contractual life, Vested and expected to vest	7 years 7 months 6 days

Stock-Based Compensation - Su57

Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Units [Member] - shares	1 Months Ended	3 Months Ended
	Jan. 31, 2017	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance	7,750	7,750
Number of shares, Granted	91,150	238,550
Number of shares, Vested		(7,750)
Number of shares, Expired/forfeited/cancelled		(750)
Number of shares, ending balance		237,800
Number of shares, Expected to vest		237,800

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)Segment	Mar. 31, 2016USD ($)
Segment Reporting Information [Line Items]
Number of business segments | Segment	2
Revenue	$ 18,742,000	$ 17,742,000
Acute Care [Member]
Segment Reporting Information [Line Items]
Revenue	$ 0

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Segment Reporting Information [Line Items]
Revenues	$ 18,742,000	$ 17,742,000
Operating income (loss)	(7,302,000)	(5,025,000)
Depreciation and amortization	1,842,000	1,917,000
Capital expenditures	1,744,000	344,000
Total assets	176,074,000		$ 182,997,000
CDMO [Member]
Segment Reporting Information [Line Items]
Revenues	18,742,000	17,742,000
Operating income (loss)	6,199,000	5,644,000
Depreciation and amortization	1,837,000	1,917,000
Capital expenditures	1,530,000	344,000
Total assets	75,588,000		77,828,000
Acute Care [Member]
Segment Reporting Information [Line Items]
Revenues	0
Operating income (loss)	(13,501,000)	$ (10,669,000)
Depreciation and amortization	5,000
Capital expenditures	214,000
Total assets	$ 100,486,000		$ 105,169,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Malvern Consulting Group, Inc. (MCG) [Member] $ in Thousands	Jan. 02, 2017	Mar. 31, 2017	Mar. 31, 2016USD ($)	Dec. 31, 2016ft²
Related Party Transaction [Line Items]
Related party transaction expenses			$ 101
MCG consultants service fee description		MCG provided the Company with certain consulting services for a fee based upon hourly rates
Aggregate area of office and lab space | ft²				8,458
Payment of rental fees			$ 51
Lease directly with the landlord	6 years	6 years